Non-small cell lung cancer
Conditions
Interventions
Sponsors
Okayama University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Histologically or cytologically proven NSCLC 2)EGFR mutation (exon19 deletion or L858R in exon 21) without T790M proven by rebiopsy after PD of prior therapy 3)Age: over 20 4)PS(ECOG): 0-1 5)Unresectable clinical stage IIIB/IV 6)Previously treated with EGFR-TKI (only 1 regimen) and lasted for more than 6 months 7)Previously treated with plutinum combination chemotherapy 8)After 3rd line therapy 9)Interval of radiation therapy: 4 weeks after thoracic RT and 1 week after non-thoracic RT 10)Measurable disease for RECIST 11)Adequate organ functions judged by laboratory tests 12)Life expectancy: over 3 months 13)Written informed consent
Exclusion criteria
Exclusion criteria: 1)SCLC and sarcoma peoven by rebiopsy 2)Symptomatic brain metastases 3)Leptomeningeal carcinomatosis 4)Active double cancer 5)Severe allergic history 6)Pregnancy 7)Svere complication 8)Indicated for urgent RT 9)Allergic history for afatinib 10)Inadequate patients whom physitians considered
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival | — |
Countries
Japan
Contacts
Public ContactNaohiro Oda
Okayama University Hospital Department of Respiratory Medicine
Outcome results
None listed